Medical
About Us
- Site Map
- Contact Us
- En|Jp
Our Fields
Sustainability
Environment
Social
- En
- Jp
Publication
Fecal Immunochemical Test: Publications
National guidelines
| Halloran S, Launoy G, Zappa M. European Commission. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition – Faecal Occult Blood Testing. Endoscopy 2012; 44:SE65–SE87. PubMed > |
| National Institute for Health and Care Excellence. NICE guideline NG12. Suspected cancer: recognition and referral. Published 2015. NICE website > |
|
U.S. Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. PubMed > |
| U.S. Multi-Society Task Force. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2017; Volume 153, Issue 1, 307-323. PubMed > |
| Canadian Task Force on Preventive Health Care. Recommendations on screening for colorectal cancer in primary care. CMAJ Mar 2016, 188 (5) 340-348. PubMed > |
| Lin JS, Piper M, Perdue LA, et al. Screening for Colorectal Cancer: A Systematic Review for the US Preventive Services Task Force: Evidence Synthesis No. 135. Rockville, MD: Agency for Healthcare Research and Quality; 2016. AHRQ publication 14 05203-EF-1. PubMed > |
Screening program
| Steele RJ, McDonald PJ, Digby J, et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United European Gastroenterol J. 2013;1(3):198-205. PubMed > |
| Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366(8):697-706. PubMed > |
| Zubero MB, Arana-Arri E, Pijoan JI, et al. Population-based colorectal cancer screening: comparison of two fecal occult blood test. Front Pharmacol. 2014;4:175. PubMed > |
| Faivre J, Dancourt V, Denis B, et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. Eur J Cancer. 2012;48(16):2969-76. PubMed > |
| Rubeca T, Rapi S, Confortini M, et al. Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series. Int J Biol Markers. 2006;21(3):157-61. PubMed > |
| Chiang TH, Chuang SL, Chen SL, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology. 2014;147(6):1317-26. PubMed > |
| van Rossum LG, van Rijn AF, Laheij RJ, et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer. 2009;101(8):1274-81. PubMed > |
| van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut. 2013;62(3):409-15. PubMed > |
| Sali L, Grazzini G, Carozzi F, et al. Screening for colorectal cancer with FOBT, virtual colonoscopy and optical colonoscopy: study protocol for a randomized controlled trial in the Florence district (SAVE study). Trials. 2013 Mar 15;14:74. PubMed > |
| Santare D, Kojalo I, Huttunen T, et al. Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use. Eur J Gastroenterol Hepatol. 2015;27(5):536–543. PubMed > |
| Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015;121(18):3221-9. PubMed > |
OC-SENSOR performance evaluation
| Vilkin A, Rozen P, Levi Z, et al. Performance Characteristics and Evaluation of an Automated-Developed and Quantitative, Immunochemical, Fecal Occult Blood Screening Test. Am J Gastroenterol. 2005;100(11):2519-25. PubMed > |
|
Miki I, Maki H, Ikuhiro M, Yoh H. Evaluation of the analytical performance of the new compact, tabletop, discrete-type automated clinical chemistry analyzer "OC-SENSOR Ceres" for fecal occult blood testing. The Journal of Clinical Laboratory Instruments and Reagents. 2021; 44(3):258-264. “We evaluated the analytical performance of OC-SENSOR Ceres in fecal occult blood quantification and obtained overall good results. “ |
Hemoglobin concentration and risk of colorectal cancer
| Chen LS, Yen AM, Chiu SY, et al. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol. 2011;12(6):551-8. PubMed > |
| Peng SM, Chiu HM, Jen HH, et al. Quantile-based fecal hemoglobin concentration for assessing colorectal neoplasms with 1,263,717 Taiwanese screenees. BMC Med Inform Decis Mak. 2019;19(1):94. PubMed > |
| Grobbee EJ, Schreuders EH, Hansen BE, et al. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia. Gastroenterology. 2017;153(5):1251-1259.e2. PubMed > |
FIT test number
| Goede SL, van Roon AH, Reijerink JC, et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut. 2013;62(5):727-34. PubMed > |
| Oort FA, van Turenhout ST, Coupé VM, et al. Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study. BMC Cancer. 2011;11:434. PubMed > |
FIT and interval cancer
| Portillo I, Arana-Arri E, Idigoras I, et al. Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain). World J Gastroenterol. 2017;23(15):2731-2742. PubMed > |
| Digby J, Fraser CG, Carey FA, et al. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited. J Med Screen. 2016;23(3):130-4. PubMed > |
Comparison with gFOBT
| Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst. 2011;103(23):1741-51. PubMed > |
| van Rossum LG, van Rijn AF, Laheij RJ, et al. Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population. Gastroenterology, 2008;135(1):82-90. PubMed > |
| Rabeneck L, Rumble RB, Thompson F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol. 2012;26(3):131-47. PubMed > |
| van Rossum LG, van Rijn AF, Verbeek AL, et al. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. Int J Cancer. 2011;128(8):1908-17. PubMed > |
